ArticleJACC. Basic to translational science2025
Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial.
Article in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Lipoprotein(a) and oxidized phospholipids are associated with myocardial inflammation after acute myocardial infarction.Nature cardiovascular research · 2026Trial
- Immuno-instructive biomaterials for coronary artery disease and myocardial infarction repair.Journal of materials science. Materials in medicine · 2026Review
- Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Article
- Pillars of Peer Review.JACC. Basic to translational science · 2026Article
- The Impact of Single-Dose Alirocumab on Efficacy and Safety After Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Single-Center Retrospective Real-World Study.Reviews in cardiovascular medicine · 2026Article
- Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice.Current atherosclerosis reports · 2026Review
- Molecular contrast agents for post-infarct cardiac remodelling: a contemporary review.European heart journal. Imaging methods and practice · 2026Review
- The biology of lipoprotein(a): From genetics to molecular mechanisms.European journal of clinical investigation · 2026Review
- Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Immune-Inflammatory Responses in the Acute Phase of Ischemic Stroke.Journal of inflammation research · 2026Article
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions.MedComm · 2025Review
- Do Anti-PCSK9 Monoclonal Antibodies Have Pleiotropic Effects?JACC. Basic to translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a randomized trial with 55 participants from the EVACS (Evolocumab in Acute Coronary Syndrome) trials, patients with non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI received a single dose of evolocumab or placebo, with myocardial inflammation assessed via
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.